AbbVie had a strong Q1 performance in its oncology, neuroscience, and immunology franchises. Read why I continue to rate ABBV ...

Brokerages cut their target price on Maruti Suzuku as the auto firm's Q4 numbers were a miss, prompting tepid FY2026 expectations and margin headwinds.